A Randomized, Double-blind, Parallel Groups, Phase 1 Clinical Study Comparing the Pharmacokinetic, Safety and Immunogenicity of Adalimumab in Healthy Subjects
The study aims to evaluate the pharmacokinetic profile, safety profile, and immunogenic potential of adalimumab of a new citrate-free formulation of adalimumab (Adalimumab Richmond) [Test Product] vs. Humira® AC Pen [Reference Product]
100 项与 Custom Biologics 相关的临床结果
0 项与 Custom Biologics 相关的专利(医药)
100 项与 Custom Biologics 相关的药物交易
100 项与 Custom Biologics 相关的转化医学